简体中文
|
繁體中文
|
English
Home
News
Events
Media Services
About Us
About Interfax
Contact Us
Health and Pharmaceutical Press Releases
2018-12-05 13:58
ResMed to Acquire Propeller Health, a Leader in COPD and Asthma Connected Health Solutions, for $225 Million
2018-12-04 18:30
Takeda Announces Execution of Loan Agreement in Connection with Proposed Acquisition of Shire plc
2018-12-04 16:46
Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting
2018-12-04 16:08
Tiziana Completes Patient Enrollment in a Phase 2a Trial to Evaluate Tolerability and Anti-Tumor Activity of Milciclib in Hepatocellular Carcinoma (HCC)
2018-12-04 14:39
ACM Global Laboratories Appoints Brian Wright as President
2018-12-04 09:54
Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018
2018-12-04 09:50
Vitruvias Therapeutics Inc., and Sunny Pharmtech Inc., Announce the FDA Approval of Generic Aminocaproic Acid 500 mg and 1000 mg Tablets
2018-12-03 10:28
Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018
2018-12-03 10:26
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session
2018-12-03 10:24
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018
2018-12-03 10:22
Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018
2018-11-30 11:43
FDA Clears SpinalCyte IND Application for Universal Donor Cell Therapy to Treat Lower Back Pain
2018-11-29 18:44
European Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib, Advancing Treatment Paradigm in Europe
2018-11-27 16:02
American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway
2018-11-23 10:19
Vineti™ to Partner With Tessa Therapeutics™ to Advance and Scale Cancer Immunotherapies World-Wide
2018-11-22 15:46
ResMed Elects Harjit Gill to Its Board of Directors
2018-11-21 16:40
While China Investigates Marriott’s Dirty Rooms, UNITE HERE Offers Briefing with Housekeepers
2018-11-21 13:44
NAMSA Launches Chinese Website to Provide Medical Device Development Resource to APAC Sponsors
2018-11-21 13:22
From Niche to Normal – Cannabis Use Becoming More Accepted in the United States
2018-11-20 12:26
Alvotech and Fuji Pharma Enter into Exclusive Partnership for Development and Commercialization of Biosimilars in Japan
<< First
< Previous
187
188
189
190
191
192
193
194
195
196
Next >
Last >>
39251
39242
39241
39239
39238
39230
39228
39219
39218
39217
39216
39206
39201
39178
39164
39162
39152
39145
39144
39134
Business Wire Weibo
Press Releases
Corporate Social Responsibility
Manufacturing
Chemical
Health and Pharmaceutical
Property
Travel
Automotive
Life and Entertainment
Energy and Environmental
Retail
Transportation
Business and E-commerce
Communications and Media
Metals and Mining
Finance
Technology
Sports
Education
Art and Culture
Legal
Latest Releases
2026-11-18 16:19
Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption
2026-11-18 16:12
Sparxity Appoints former Cray CEO Peter Ungaro and Semiconductor Veteran Daniel Armbrust to its Advisory Board
2026-11-18 16:06
KBRA Announces Appointment of Brett Hemsley as Head of Asia-Pacific Strategy
2026-11-18 16:02
Quaise Energy Signs 50 MW Geothermal Power Purchase Agreement with Google
2026-11-18 14:15
ZCG Appoints Pierre Garnier as Managing Director, Global Head of Capital Formation